Zydus Lifesciences has announced the dissolution of its subsidiary, Ampliman 1, France, effective January 16, 2026. Ampliman 1 was a wholly-owned subsidiary of Zydus MedTech (France) S.A.S. All assets and liabilities have been transferred to Zydus MedTech (France) S.A.S. The company has clarified that this dissolution will not impact the overall business operations of Zydus Lifesciences. Furthermore, Auroralux S.A.S. and Ampliman 2 were also dissolved without liquidation.
Dissolution of Subsidiary
Zydus Lifesciences announced the dissolution of Ampliman 1, located in France, effective January 16, 2026. This decision follows earlier intimations regarding the dissolution of Auroralux S.A.S. (Luxembourg) and Ampliman 2 (France).
Details of the Dissolution
Ampliman 1 was a wholly-owned subsidiary of Zydus MedTech (France) S.A.S., which itself is a step-down subsidiary of Zydus Lifesciences. Upon the dissolution of Ampliman 1, all assets and liabilities have been transferred to Zydus MedTech (France) S.A.S.
Impact on Operations
The company has stated that the dissolution of Ampliman 1 will not have any impact on its business operations. Additionally, Auroralux S.A.S., Ampliman 1, and Ampliman 2, all previous holding companies of Amplitude Surgical, France, were dissolved without liquidation, Zydus MedTech (France) SAS now holds the entire share capital of Amplitude Surgical, France.
Source: BSE
